Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ICML 2019 | Ibrutinib for the treatment of Bing-Neel syndrome

Steven Treon • 20 Jun 2019
ICML 2019
B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Rare Diseases Waldenström’s Macroglobulinemia Ibrutinib

Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the retrospective, multicenter study of ibrutinib for the treatment of Bing-Neel syndrome. This syndrome is becoming more common as people live longer with Waldenström’s macroglobulinemia. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Steven Treon

The impact of TP53 mutations on the prognosis of patients with Waldenström’s macroglobulinemia
1:18
The impact of TP53 mutations on the prognosis of patients with Waldenström’s macroglobulinemia
Steven Treon • 19 Jun 2025
Novel treatment modalities emerging for WM: bispecifics, CAR T-cells & combinations with BTKis
1:13
Novel treatment modalities emerging for WM: bispecifics, CAR T-cells & combinations with BTKis
Steven Treon • 19 Jun 2025
Exciting developments in Waldenström’s macroglobulinemia: insights from a 'Meet the Expert' session
2:56
Exciting developments in Waldenström’s macroglobulinemia: insights from a 'Meet the Expert' session
Steven Treon • 19 Jun 2025
Treatment approaches for symptomatic, treatment-naive WM versus previously treated patients
1:49
Treatment approaches for symptomatic, treatment-naive WM versus previously treated patients
Steven Treon • 19 Jun 2025

Related Videos

Federated learning to train generative AI models for diagnosis & prognosis of hematological diseases
2:08
Federated learning to train generative AI models for diagnosis & prognosis of hematological diseases
Steven Treon • 7 Dec 2025
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Steven Treon • 6 Dec 2025
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
2:10
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
Steven Treon • 8 Dec 2025
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
2:42
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
Steven Treon • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals